MXPA05008909A - Formulacion intranasal de rotigotina. - Google Patents
Formulacion intranasal de rotigotina.Info
- Publication number
- MXPA05008909A MXPA05008909A MXPA05008909A MXPA05008909A MXPA05008909A MX PA05008909 A MXPA05008909 A MX PA05008909A MX PA05008909 A MXPA05008909 A MX PA05008909A MX PA05008909 A MXPA05008909 A MX PA05008909A MX PA05008909 A MXPA05008909 A MX PA05008909A
- Authority
- MX
- Mexico
- Prior art keywords
- rotigotine
- intranasal formulation
- cyclodextrin
- alpha
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion pertenece a una formulacion farmaceutica intranasal liquida que comprende una sal de adicion de acido farmaceuticamente aceptable de rotigotina y (-ciclodextrina, de preferencia en la forma de una solucion acuosa tamponada que tiene una viscosidad de 0.5-1.5mm2/s.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03029680A EP1547592A1 (en) | 2003-12-23 | 2003-12-23 | Intranasal formulation of rotigotine |
PCT/EP2004/014626 WO2005063236A1 (en) | 2003-12-23 | 2004-12-22 | Intranasal formulation of rotigotine |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008909A true MXPA05008909A (es) | 2005-10-05 |
Family
ID=34530709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008909A MXPA05008909A (es) | 2003-12-23 | 2004-12-22 | Formulacion intranasal de rotigotina. |
Country Status (28)
Country | Link |
---|---|
US (1) | US7683040B2 (es) |
EP (2) | EP1547592A1 (es) |
JP (1) | JP4430067B2 (es) |
KR (1) | KR100718760B1 (es) |
CN (1) | CN100374112C (es) |
AT (1) | ATE326961T1 (es) |
AU (1) | AU2004308641B2 (es) |
BR (1) | BRPI0407845A (es) |
CA (1) | CA2516400C (es) |
CY (1) | CY1105131T1 (es) |
DE (1) | DE602004000982T2 (es) |
DK (1) | DK1605932T3 (es) |
EA (1) | EA008005B1 (es) |
ES (1) | ES2262122T3 (es) |
HK (1) | HK1083596A1 (es) |
HR (1) | HRP20060240T3 (es) |
IL (1) | IL170297A (es) |
IS (1) | IS2310B (es) |
MX (1) | MXPA05008909A (es) |
NO (1) | NO20054018L (es) |
NZ (1) | NZ541875A (es) |
PL (1) | PL1605932T3 (es) |
PT (1) | PT1605932E (es) |
RS (1) | RS50534B (es) |
SI (1) | SI1605932T1 (es) |
UA (1) | UA79196C2 (es) |
WO (1) | WO2005063236A1 (es) |
ZA (1) | ZA200506550B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
MX2010005925A (es) | 2007-11-28 | 2010-08-02 | Ucb Pharma Gmbh | Nueva forma polimorfico de rotigotina y proceso para la produccion. |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
SI2515887T1 (sl) | 2009-12-22 | 2018-10-30 | Ucb Biopharma Sprl | Polivinilpirolidon za stabilizacijo trdne disperzije nekristalinične oblike rotigotina |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
CN103768043B (zh) * | 2012-10-22 | 2015-12-09 | 苏州药明康德新药开发股份有限公司 | 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法 |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
EP3108245B1 (en) | 2014-02-18 | 2020-07-22 | Robert I. Henkin | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
CA2948220C (en) | 2014-05-20 | 2023-06-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
EP4238580A3 (en) | 2014-05-20 | 2023-10-25 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
CN110917125B (zh) * | 2020-01-02 | 2022-08-12 | 安徽中医药大学 | 一种罗替戈汀鼻用胶束温敏凝胶的制备方法 |
WO2023133463A1 (en) * | 2022-01-06 | 2023-07-13 | Cyrano Therapeutics, Inc. | Improved nasal administration of parkinson's therapeutics |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108991A (en) * | 1975-06-19 | 1992-04-28 | Whitby Research, Inc. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US5218113A (en) * | 1986-01-31 | 1993-06-08 | Whitby Research, Inc. | N-substituted thiolactams |
US4992422A (en) * | 1986-01-31 | 1991-02-12 | Whitby Research, Inc. | Compositions comprising 1-substituted azacycloalkanes |
AU592629B2 (en) * | 1986-01-31 | 1990-01-18 | Whitby Research, Inc. | Compositions comprising 1-substituted azacycloalkanes and their uses |
US4755535A (en) * | 1986-04-23 | 1988-07-05 | Nelson Research & Development Co. | Compositions comprising 1-substituted azacycloalkenes |
US5073544A (en) | 1986-08-15 | 1991-12-17 | Whitby, Inc. | Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes |
US4902676A (en) * | 1986-09-29 | 1990-02-20 | Nelson Research & Development Co. | Compositions comprising N,N-dialkylalkanamides |
DE3868866D1 (de) * | 1987-11-20 | 1992-04-09 | Erba Carlo Spa | Ergolinderivate mit antiparkinsonwirkung. |
US5472946A (en) * | 1988-04-08 | 1995-12-05 | Peck; James V. | Transdermal penetration enhancers |
US5073844A (en) * | 1991-01-11 | 1991-12-17 | The Annlouise Partnership | Lighted baggage piece |
US6086905A (en) * | 1991-03-21 | 2000-07-11 | Peck; James V. | Topical compositions useful as skin penetration barriers |
US5308625A (en) * | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
US5756483A (en) | 1993-03-26 | 1998-05-26 | Merkus; Franciscus W. H. M. | Pharmaceutical compositions for intranasal administration of apomorphine |
GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
US5771890A (en) * | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
DK0766578T3 (da) | 1994-06-24 | 2000-10-23 | Cygnus Therapeutic Systems | Iontophoretisk prøvetagningsindretning |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
ATE251901T1 (de) | 2001-05-08 | 2003-11-15 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson |
FR2829028B1 (fr) * | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
AU2003223579A1 (en) * | 2002-04-18 | 2003-11-03 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
CA2503381A1 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
US9102726B2 (en) * | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
CA2554616A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
WO2006015737A1 (de) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
DE102004054634A1 (de) | 2004-11-12 | 2006-05-18 | Schwarz Pharma Ag | Azaindolcarboxamide |
-
2003
- 2003-12-23 EP EP03029680A patent/EP1547592A1/en not_active Withdrawn
-
2004
- 2004-12-22 PL PL04804221T patent/PL1605932T3/pl unknown
- 2004-12-22 JP JP2006508291A patent/JP4430067B2/ja not_active Expired - Fee Related
- 2004-12-22 US US10/545,530 patent/US7683040B2/en not_active Expired - Fee Related
- 2004-12-22 ES ES04804221T patent/ES2262122T3/es active Active
- 2004-12-22 BR BRPI0407845-4A patent/BRPI0407845A/pt not_active IP Right Cessation
- 2004-12-22 UA UAA200508587A patent/UA79196C2/uk unknown
- 2004-12-22 CA CA002516400A patent/CA2516400C/en not_active Expired - Fee Related
- 2004-12-22 MX MXPA05008909A patent/MXPA05008909A/es active IP Right Grant
- 2004-12-22 KR KR1020057017173A patent/KR100718760B1/ko not_active IP Right Cessation
- 2004-12-22 NZ NZ541875A patent/NZ541875A/en unknown
- 2004-12-22 SI SI200430027T patent/SI1605932T1/sl unknown
- 2004-12-22 PT PT04804221T patent/PT1605932E/pt unknown
- 2004-12-22 EP EP04804221A patent/EP1605932B1/en not_active Not-in-force
- 2004-12-22 DK DK04804221T patent/DK1605932T3/da active
- 2004-12-22 RS YUP-2006/0653A patent/RS50534B/sr unknown
- 2004-12-22 AT AT04804221T patent/ATE326961T1/de active
- 2004-12-22 DE DE602004000982T patent/DE602004000982T2/de active Active
- 2004-12-22 WO PCT/EP2004/014626 patent/WO2005063236A1/en active IP Right Grant
- 2004-12-22 AU AU2004308641A patent/AU2004308641B2/en not_active Ceased
- 2004-12-22 EA EA200501159A patent/EA008005B1/ru not_active IP Right Cessation
- 2004-12-22 CN CNB2004800109827A patent/CN100374112C/zh not_active Expired - Fee Related
-
2005
- 2005-08-16 IL IL170297A patent/IL170297A/en not_active IP Right Cessation
- 2005-08-16 ZA ZA200506550A patent/ZA200506550B/en unknown
- 2005-08-30 NO NO20054018A patent/NO20054018L/no not_active Application Discontinuation
-
2006
- 2006-05-18 HK HK06105750A patent/HK1083596A1/xx not_active IP Right Cessation
- 2006-05-26 IS IS8487A patent/IS2310B/is unknown
- 2006-07-07 HR HR20060240T patent/HRP20060240T3/xx unknown
- 2006-08-09 CY CY20061101113T patent/CY1105131T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05008909A (es) | Formulacion intranasal de rotigotina. | |
NO20061840L (no) | Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme | |
HRP20040352B1 (en) | Use of flibanserin in the treatment of sexual disorders | |
GEP20074027B (en) | Stabilized oral suspension formulation | |
MY142329A (en) | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents. | |
ZA200305412B (en) | 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical. | |
NZ597757A (en) | Aqueous insulin preparations containing methionine | |
HRP20020198B1 (en) | Moxifloxacin formulation containing common salt | |
IL179012A (en) | A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use | |
BR0209020A (pt) | Composição farmacêutica de polialilamina | |
NZ510887A (en) | Formulations of fexofenadine for ocular and nasal delivery | |
MY130441A (en) | Solutions containing epinastin | |
GEP20084340B (en) | Pharmaceutical compositions comprising fentanyl for intranasal delivery | |
DE60221227D1 (de) | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen | |
PL1663141T3 (pl) | Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę | |
WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
SE0001916D0 (sv) | Novel formulation | |
HUP0202324A2 (hu) | Prukaloprid orális oldat | |
WO2010066437A3 (de) | Wässrige zusammensetzung enthaltend dexpanthenol und natriumchlorid | |
ES2197781A1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
WO2003030862A3 (en) | Anaesthetic compositions and method for their administration | |
AU2001258754A1 (en) | Aqueous liquid preparation | |
HRP20070081T5 (en) | Nasal pharmaceutical composition of piribedil | |
PT1093810E (pt) | Comprimido de dissolucao rapida contendo brotizolam | |
MXPA04000918A (es) | Pramipexol como anticonvulsivo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |